Form 4: Aprea Therapeutics Executive John P. Hamill Acquires Additional Shares
SEC Form 4
John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, recently purchased 450 shares of the company's common stock at an average price of $2.61.
Summary
- On October 10, 2024, John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, acquired 450 shares of common stock.
- The shares were purchased at a weighted average price of $2.61.
- The purchase price ranged from $2.55 to $2.618 per share.
- Following the transaction, Hamill directly owns 19,318 shares of Aprea Therapeutics.
Sentiment
Score: 6
Explanation: Insider buying is generally viewed as a positive sign, suggesting the executive believes the company's stock is undervalued. However, the small number of shares purchased makes it a neutral indicator.
Positives
- The purchase of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/10/2024 | Date of transaction: John P. Hamill purchased 450 shares of Aprea Therapeutics common stock. |
| 10/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.